| Title |
Therapeutic Potential of Monteplase in Acute Myocardial Infarction
|
|---|---|
| Published in |
American Journal of Cardiovascular Drugs, August 2012
|
| DOI | 10.2165/00129784-200505040-00002 |
| Pubmed ID | |
| Authors |
Teruo Inoue, Ryoichi Nishiki, Manabu Kageyama, Koichi Node |
| Abstract |
Thrombolysis with conventional thrombolytic agents prior to percutaneous coronary intervention (PCI) has had no impact on the treatment of acute myocardial infarction (AMI). However, the development of mutant tissue type plasminogen activators (mt-PA) has prompted us to reassess the combination of thrombolysis and PCI. Monteplase is a newly developed mt-PA that can be administered as a single intravenous bolus injection. The results of the COMA (COmbining Monteplase with Angioplasty) trial, suggest that monteplase administration prior to emergent PCI in AMI improves 6-month outcomes and possibly the long-term prognosis of myocardial infarction. Combining monteplase administration on presentation at a community hospital with prompt transfer to a tertiary center for PCI would be an ideal strategy for the treatment of AMI. |
Mendeley readers
The data shown below were compiled from readership statistics for 9 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 9 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 1 | 11% |
| Other | 1 | 11% |
| Unknown | 7 | 78% |
| Readers by discipline | Count | As % |
|---|---|---|
| Nursing and Health Professions | 1 | 11% |
| Agricultural and Biological Sciences | 1 | 11% |
| Medicine and Dentistry | 1 | 11% |
| Unknown | 6 | 67% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 August 2016.
All research outputs
#8,534,528
of 25,371,288 outputs
Outputs from American Journal of Cardiovascular Drugs
#192
of 467 outputs
Outputs of similar age
#63,532
of 186,109 outputs
Outputs of similar age from American Journal of Cardiovascular Drugs
#46
of 127 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 467 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 186,109 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 127 others from the same source and published within six weeks on either side of this one. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.